Idera Pharmaceuticals, Inc. (IDRA)

Trade IDRA now with
8/2/2018 4:36:44 PM Idera Pharmaceuticals Q2 Loss/share $0.59 Vs. Loss $1.15 Year Ago
7/16/2018 6:21:10 AM Wedbush Is Lowering Idera Pharmaceuticals, Inc. (IDRA) FY18 Estimate To -0.40 From -0.37
7/16/2018 6:20:54 AM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) Q4 18 Estimate To -0.11 From -0.10
7/16/2018 6:20:20 AM Wedbush Is Increasing Idera Pharmaceuticals, Inc. (IDRA) Q3 18 Estimate To -0.08 From -0.09
7/16/2018 6:19:51 AM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) Q2 18 Estimate To -0.10 From -0.09
7/10/2018 4:10:46 PM Idera Pharmaceuticals, Trading Expected To Resume At 4:30 PM ET
7/10/2018 4:04:26 PM BioCryst Pharma Announces Termination Of Merger Agreement With Idera Pharma
7/10/2018 4:03:55 PM Idera Pharmaceuticals, Trading Halt Pending News
6/12/2018 7:31:40 AM Idera Pharma: Phase 2 Trial Of IMO-8400 Did Not Meet Primary Endpoint Of Statistically Significant Reduction Of CDASI
6/12/2018 7:30:17 AM Idera Pharmaceuticals Reports Results From Phase 2 Trial Of IMO-8400 In Dermatomyositis
6/4/2018 7:36:27 AM Idera Pharma Presents Clinical Data From ILLUMINATE-204 Trial Of Combination Of Tilsotolimod And Ipilimumab
5/9/2018 7:19:10 AM Idera Pharma Q1 Loss Applicable To Stockholders $20.1 Mln Or $0.10/Shr Vs Loss $15.1 Mln Or $0.10/Shr Last Year
4/17/2018 7:09:01 AM Idera Pharma Presents Pre-Clinical Data Demonstrating Potential For IMO-2125 In Combination With Checkpoint Inhibitors
4/16/2018 7:11:13 AM Idera Pharma Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation
4/10/2018 7:33:07 AM BioCryst And Idera Reschedule Meetings To Vote On Proposed Merger To July 10, 2018